loading page

  • +5
  • Vishwa CR,
  • Gargi Das,
  • Rachna Seth,
  • Savita Sapra,
  • Prasanth Siri,
  • Jagdish Meena,
  • Aditya Gupta,
  • Sreenivas Vishnubhatla
Vishwa CR
All India Institute of Medical Sciences

Corresponding Author:[email protected]

Author Profile
Gargi Das
All India Institute of Medical Sciences
Author Profile
Rachna Seth
All India Institute of Medical Sciences
Author Profile
Savita Sapra
All India Institute of Medical Sciences
Author Profile
Prasanth Siri
All India Institute of Medical Sciences
Author Profile
Jagdish Meena
All India Institute of Medical Sciences
Author Profile
Aditya Gupta
Childrens Hospital at Westmead
Author Profile
Sreenivas Vishnubhatla
AIIMS, New Delhi
Author Profile


BACKGROUND: Neurocognitive deficits are an important late effect in survivors of acute lymphoblastic Leukemia(ALL). Data from low middle income countries is scarce and highly influenced by biological and cultural variations. Such data would be useful for highlighting the importance of early intervention in an already disadvantaged population. PROCEDURE: 70 consecutive survivors of childhood ALL were evaluated for neurocognitive deficits by the Indian adaptation of Wechsler Intelligence Scale for Children-Fourth Edition(WISC-INDIA). Prevalence of neurocognitive deficits was calculated based on Full Scale Intelligence Quotient(FSIQ) and scores in discrete domains like Verbal Comprehension, Perceptual Reasoning, Working Memory and Processing Speed were calculated and compared to baseline characteristics, chemotherapy and radiation dose received. RESULTS: The mean FSIQ was 86.1 ± 20.5, with significant neurocognitive deficit(FSIQ <90) being prevalent in 50%(95% CI 38% to 62%) of the cohort. The proportion of survivors with deficits in individual domains of verbal comprehension, perceptual reasoning, working memory and processing speed were 49%, 50%, 47% and 44% respectively. The odds of having deficits in neurocognitive function was higher when a child belonged to lower socioeconomic strata, had parents with less than primary school education and whose birth order was higher(All p<0.05). Age at diagnosis, current age at assessment, receiving lower or higher dose of radiotherapy, high dose methotrexate or cytarabine did not have a direct impact on neurocognitive function. CONCLUSIONS AND RELEVANCE: The current need is to develop country specific neurocognition assessment tools to initiate early screening and develop culturally appropriate preventive and rehabilitative interventions.
27 May 2021Submitted to Pediatric Blood & Cancer
27 May 2021Submission Checks Completed
27 May 2021Assigned to Editor
31 May 2021Reviewer(s) Assigned
18 Jun 2021Review(s) Completed, Editorial Evaluation Pending
19 Jun 2021Editorial Decision: Revise Major
12 Sep 2021Submission Checks Completed
12 Sep 20211st Revision Received
12 Sep 2021Assigned to Editor
13 Sep 2021Reviewer(s) Assigned
30 Sep 2021Review(s) Completed, Editorial Evaluation Pending
01 Oct 2021Editorial Decision: Revise Major
29 Nov 20212nd Revision Received
29 Nov 2021Submission Checks Completed
29 Nov 2021Assigned to Editor
30 Nov 2021Reviewer(s) Assigned
15 Dec 2021Review(s) Completed, Editorial Evaluation Pending
16 Dec 2021Editorial Decision: Revise Minor
07 Mar 2022Assigned to Editor
07 Mar 2022Submission Checks Completed
07 Mar 20223rd Revision Received
08 Mar 2022Review(s) Completed, Editorial Evaluation Pending
08 Mar 2022Editorial Decision: Accept